At the Cutting Edge

What we asked: What big changes in drug development and manufacturing would you like to see in the next 10 years?

Response from: Alexander Seyf, CEO, Autolomous

“The integration of digital technology has dramatically refined our approach to scientific data collection, enhancing the precision and efficiency of research. I believe that AI and ML are set to take the capabilities of cell and gene therapies to unprecedented heights. By harnessing AI to analyze vast datasets, researchers can uncover patterns and predict outcomes much more rapidly than traditional methods allow. This integration of AI and ML could not only accelerate the development process, but enhance the precision of cell and gene therapies, leading towards a more robotized and automated future in medicine.

“Imagine a world where cutting-edge therapies are not only developed in distant, centralized labs, but are seamlessly integrated into a “lab-by-the-bed” setting. Such a model could leverage digital data, collaborative platforms, and standardized processes to drastically reduce costs and expand access to personalized, effective treatments. By adopting global standards and fostering international collaborations, CGT can be made available universally, ensuring equitable healthcare outcomes across all demographics.

“Sharing unsuccessful outcomes will also be as crucial as celebrating breakthroughs. By openly discussing what doesn’t work, the scientific community can avoid repeating past mistakes, thereby preventing potential setbacks and disasters in cell and gene therapy development. A transparent approach to failure will help foster a culture of continuous improvement and safety.”

Read over 100 other views on the future of the pharma industry on our special web page.